三生国健股价涨5.13%，泰信基金旗下1只基金重仓，持有21.48万股浮盈赚取58.65万元

Company Overview - Sanofi Guojian Pharmaceutical Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 25, 2002. The company went public on July 22, 2020. Its main business involves the research, production, and sales of antibody drugs [1] - The revenue composition of the company includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Stock Performance - On September 24, the stock price of Sanofi Guojian increased by 5.13%, reaching 55.99 CNY per share, with a trading volume of 273 million CNY and a turnover rate of 0.81%. The total market capitalization is 34.534 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Taixin Fund has a significant position in Sanofi Guojian. The Taixin Medical Service Mixed Initiation A Fund (013072) held 214,800 shares in the second quarter, accounting for 5.15% of the fund's net value, making it the sixth-largest holding [2] - The Taixin Medical Service Mixed Initiation A Fund was established on December 29, 2021, with a latest scale of 31.5558 million CNY. Year-to-date returns are 40.41%, ranking 1725 out of 8173 in its category, while the one-year return is 75.06%, ranking 1478 out of 7996 [2] Fund Manager Information - The fund manager of Taixin Medical Service Mixed Initiation A Fund is Chen Ying, who has been in the position for 3 years and 252 days. The total asset size of the fund is 564 million CNY, with the best return during the tenure being 37.02% and the worst return being -5.65% [3]